Business
Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form
Cannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Study Shows Cannabinoids CBNA and CBCA Cause Necrosis Similarly to their Non-acidic Form\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Feb. 18, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Feb. 18, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the cannabinoids CBN (Cannabinol) and CBC (Cannabichromene) and their acidic form were shown to have necrotic effects on human colon cancer cells in a pre-clinical study held at the company's High Throughput Screening (HTS) facility in Israel. \n\n \n \n\n \nCBN is a mildly psychoactive cannabinoid found only in trace amounts in Cannabis. Degraded or oxidized cannabis oils have high CBN concentration. CBN is the degraded product of Tetrahydrocannabinolic acid (THCA). THCA will convert to Cannabinolic acid (CBNA) when exposed to air or ultraviolet light for a prolonged period of time. CBN is then formed by decarboxylation of CBNA.\nThe findings obtained at the lab are complementary to our previous results, indicating that some cannabinoids are more toxic to cancer cells in their carboxylated form and some in their acidic form.\nThe company continues to screen cannabinoid compound libraries at the HTS facility in Israel, whilst seeking to create proprietary formulations targeting cancers.   \nDr. Ilan Hochman, the company's VP of R&D: \"Cannabinoids have various biological pathways which are revealed by many scientific studies. The current results add to the complexity of our observations justifying solid preclinical science as a major step before clinical validation.\"\nAbout Cannabics Pharmaceuticals\nCannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to creat...